Chinese Factory Linked to Drug Under Inquiry in U.S.
A Chinese factory that has not been inspected by the Food and Drug Administration is the source for the active ingredient of a critical blood-thinning drug whose production was suspended this week after 350 patients reported ill effects from it.
At least four people died after being given the drug, heparin.
An F.D.A. spokeswoman, Heidi Robello, said Wednesday that the agency was making plans to inspect the Chinese factory as well as a finishing plant in New Jersey “as soon as possible.”
See also “China scrutinized in blood thinner problems” from the Los Angeles Times.